Cognitive reserve (CR) refers to the brain's capacity to cope with pathology in order to minimize the symptoms. CR is associated with different outcomes in severe mental illness. This study aimed to analyze the impact of CR according to the diagnosis of first‐episode affective or non‐affective psychosis (FEP).. To read the full article, log in using your MPFT NHS OpenAthens details. SSOTP (legacy account) - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Comment. In clinical practice, patients with first-episode schizophrenia often receive a range of different antipsychotics as first-line treatment, and then undergo multiple switches to different antipsychotics in the first months of treatment if improvement does not occur. Clozapine is typically offered after many unsuccessful antipsychotic trials and years of persisting psychotic symptoms. Standardisation of treatment of first-episode schizophrenia has the potential to transform patient outcomes, and shorten the timeframe over which these outcomes are achieved.. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
Open access. Method of levels (MOL) is an innovative transdiagnostic cognitive therapy with potential advantages over existing psychological treatments for psychosis.
Commentary. ‘Deprescribing’ here comprises arguments against treating patients who have been psychotic beyond first episode. Nevertheless, four out of five patients relapse, compared with only two of five still taking medication. However, much first-episode psychosis is not schizophrenia, but persistent substance-induced psychotic disorder. Virtually nothing is known about factors which facilitate this in the minority who develop it, nor how to decide if the patient will relapse off medication. Patients who are well, stable and tolerating minimal doses of medication should be the first to suggest that they try to do without it, not us.. To read the full article, log in using your MPFT NHS OpenAthens details. SSOTP (legacy account) - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Polypharmacy and the risks of long term use of antipsychotic medications point toward the need for identifying practices for deprescribing in psychiatry. The following article gives a brief overview of key points around deprescribing antipsychotic medications in psychiatry, including identifying risks and benefits, considerations around timing, and steps involved.. To read the full article, log in using your MPFT NHS OpenAthens details. SSOTP (legacy account) - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Treatment-resistant schizophrenia (TRS) affects about one-third of individuals with schizophrenia. People with TRS do not experience sustained symptom relief and at the same time have the most severe disease-related disability and associated costs among individuals with severe mental disorders. Like caregivers of people with treatment-responsive schizophrenia, caregivers of individuals with TRS experience the disease burden along with their care recipients; however, for those providing care for individuals with TRS, the stress of the burden is unrelenting due to uncontrolled symptoms and a lack of effective treatment options. The objective of this study is to better understand the burden of TRS from the caregiver perspective and to explore their perception of available treatments.
Open access. Brain acetylcholine is decreased even in patients with cognitively preserved Parkinson’s disease (PD). We investigated whether early and long-term use of donepezil prevents psychosis in non-demented PD patients.
Open access. Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patients with first episode psychosis (FEP), rising the hypothesis that schizophrenia itself may be related to an abnormal regulation of prolactin secretion and to impaired glucose tolerance. The aim of this study was to compare prolactin levels, glycometabolism parameters and lipid profile between a sample of 31 drug-naive adolescents in the acute phase of FEP and a control group of 23 subjects at clinical high risk (CHR) of developing psychosis.
Open access. Schizophrenia (SCZ) is associated with increased risk of type 2 diabetes (T2D). The potential diabetogenic effect of concomitant application of psychotropic treatment classes in patients with SCZ has not yet been evaluated. The overarching goal of the Genetic Overlap between Metabolic and Psychiatric disease (GOMAP) study is to assess the effect of pharmacological, anthropometric, lifestyle and clinical measurements, helping elucidate the mechanisms underlying the aetiology of T2D.
Evidence from four RCTs suggests that bifeprunox may be effective in preventing global state deterioration and reducing positive and negative symptoms in adults with schizophrenia. However, evidence is of low to very low certainty, so no strong conclusions can be drawn.
Editorial. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
The high prevalence of smoking and cognitive deficits in schizophrenia patients is well known, but findings regarding the association between the two are contradictory, and longitudinal studies are lacking. The authors sought to examine the multi-cross-sectional association between smoking behavior and performance in specific cognitive domains and the longitudinal association between change in smoking behavior and change in cognitive functioning in a large prospective study.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
This study tested for differences of white matter integrity between treated and never-treated long-term schizophrenia patients, matched on illness duration, and for differential changes in relation to age in these two groups relative to healthy comparison subjects.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
Do 7-year-old children at familial high risk of schizophrenia spectrum disorders or bipolar disorder have neurocognitive impairments, and how do their neurocognitive profiles differ?. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Psychiatric Rehabilitation Journal (Jul 16, 2018). DOI:10.1037/prj0000309
Objective: Cognitive remediation (CR) is a promising method of improving cognitive functioning in people with schizophrenia. Nevertheless, the lived experience of participation, and whether this differs from computer game (CG) playing control conditions, remains poorly understood. This study aimed to qualitatively compare the experience of participating in these 2 interventions.. To read the full article, log in using your NHS OpenAthens details.
We're expanding our Be Aware updates and want to know what physical health topics you'd like to keep updated on. Let us know your ideas by replying to this email with 'physical health topics' followed by your suggestions
International treatment guidelines recommend cognitive-behavioral therapies for people with psychosis, but implementation remains problematic. This column reports on local work to improve implementation and two recent initiatives by the National Health Service in England. The aim is to operationalize key facilitators of implementation, including adequate training, time for delivery, and supervision; systems to identify the target caseload and monitor access, provision, and outcomes; effective pathways for offering and delivering therapy; and organizational support. With these facilitators in place, new investment translates readily into effective delivery. Still, achieving universal access to cognitive-behavioral therapies may require an alternative model.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai